Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9NNX6
UPID:
CD209_HUMAN
Alternative names:
C-type lectin domain family 4 member L; Dendritic cell-specific ICAM-3-grabbing non-integrin 1
Alternative UPACC:
Q9NNX6; A8KAM4; A8MVQ9; G5E9C4; Q2TB19; Q96QP7; Q96QP8; Q96QP9; Q96QQ0; Q96QQ1; Q96QQ2; Q96QQ3; Q96QQ4; Q96QQ5; Q96QQ6; Q96QQ7; Q96QQ8
Background:
The CD209 antigen, also known as C-type lectin domain family 4 member L or Dendritic cell-specific ICAM-3-grabbing non-integrin 1, plays a pivotal role in the immune system. It functions as a pathogen-recognition receptor on immature dendritic cells, facilitating the endocytosis of pathogens for degradation. This process is crucial for the initiation of the primary immune response, including the presentation of pathogen-derived antigens to T-cells, thereby activating the adaptive immune response. Additionally, CD209 acts as an attachment receptor for various pathogens, including HIV, Ebolavirus, and Influenzavirus A, highlighting its significance in microbial infection defense.
Therapeutic significance:
Understanding the role of CD209 antigen could open doors to potential therapeutic strategies.